The main objectives of IPSE are to: (a) establish a consensus Infection Control Professional core curriculum and inventory of courses, (b) produce deliverables providing managers and health services staff with timely and periodic information and indicators of the morbidity of HAI, (c) make available evidence-based guidelines and educational tools to better and effectively manage the risk of HAI and AMR. Early detection and response to nosocomial outbreaks of known or new pathogens, including multiple resistant organisms should progress (2002/77/EC). The project is intended to foster the containment of the emergence and spread of multiple resistant organisms in the ICU through an integrated surveillance programme and provide educational support to new HAI surveillance networks. Finally a consensus on surveillance of healthcare-associated infections in EU nursing homes is necessary.


To provide realistic estimates of the burden of disease and the costs attributable to infections caused by antimicrobial resistant pathogens in Member States and Accession Countries of the European Union. The strategic goals pursued in the general objective are: - To provide valid data for politicians, policy-makers and public health experts that will allow informed estimates of the burden and the costs of AMR on a national level - To allow a comparison of costs between countries of the European Region. - Recommendations for participating countries/hospitals for implantation effective measures to keep costs caused by AMR to a minimum. - To inform public health authorities throughout Europe, in order to prioritise and plan future health political goals, as against other specific causes of morbidity and mortality in Europe


This proposal lays out the Work Programme for 2017 within the contents of the Multiannual Work Plan for the European Reference Network for Craniofacial Anomalies and ENT disorders (ERN CRANIO). ERN CRANIO involves teams from 29 European hospitals (10 Member States) that provide care, education, teaching, research and management of rare craniofacial anomalies, cleft lip/palate and ENT disorders. Our vision is that the best multidisciplinary initial care for all those with craniofacial anomalies and ENT disorders is not a privilege to be purchased but a moral right secured for all European patients.
Our MISSION is to consistently and persistently strive towards achieving our vision through:
1. Establishment and management of a steady referral network for patients with craniofacial anomalies and ENT disorders throughout Europe; 2. Improvement of the quality of care, by enhancing diagnosis, treatment and follow-up of the patients with rare craniofacial anomalies and ENT disorders; 3. Minimization of the deviation from our operational standards and sharing best practices through suitable quality improvement initiatives, while monitoring their effectiveness using measures and indicators; 4. Stimulating innovation through multicentre research projects on (genetic) causes, pathophysiology, and associated problems, and introduction of eHealth; 5. Supporting the continuous learning and development of all our members by providing high quality educational and training opportunities to medical, nursing and other healthcare professionals; 6. Disseminating gained knowledge, making it available to all stakeholders.

In Year 1, ERN CRANIO will focus on collecting and analysing the available data on diagnoses, treatment, follow-up programmes, education and eHealth. In addition, the aim is to further expand the network in the first year by including relevant partners and experts. The results of the first year will set the agenda for subsequent years.


Antimicrobial susceptibility testing of bacteria and fungi and antimicrobial resistance surveillance are closely linked together. The latter is heavily dependant on the former. There is an urgent need for European standardization and harmonization of breakpoints and reference methodology for antimicrobial susceptibility testing. Project vision: In accordance with the council recommendations 2002/77/EC, to create a pan-European network (the EUCAST General Committee) and a European standing committee (EUCAST Steering committee) with the objectives to harmonize European clinical MIC breakpoints for antibacterial and antifungal drugs and to define epidemiological cut-off values for the early detection and measurement and international comparison of antimicrobial resistance development. Furthermore, to create an interactive web-based system for the collection of MIC-values and the display of reference wild type distributions of MIC-values to be used for methodological standardization and for breakpoint setting; to offer liaison with and expertise to European dedicated surveillance networks and European regulatory bodies, and to take initiatives within education in the respective fields.


The SPIM EU project aims at contributing to the reduction of cardio-metabolic morbidity and mortality in EU Member States by establishing the feasibility of implementing innovative selective prevention actions in primary care. In addition, the SPIM EU project will provide a toolbox for tailoring selective prevention actions in all EU Member States. The evidence based guideline of the Dutch College of General Practitioners represents an innovative approach for efficiently implementing selective prevention by a stepwise identification process of persons at high risk in the general population. However, successful implementation of this approach in EU Member States with different health care systems calls for tailoring of this action.The SPIM EU project includes five Work Packages (WP4-WP8), in addition to three horizontal Work Packages. WP4 includes the mapping of existing selective prevention programs in all EU Member States, and their strengths and weaknesses. In WP5 a systematic literature review will be conducted to summarize the knowledge from the literature about facilitating and hampering factors in implementing selective prevention programs and to identify determinants of their uptake and compliance. WP6 includes a survey among primary health care professionals and a sample of the general population in five EU Member States [SWE, DNK, NLD, CZE, GRE] to gain more insight into the task perceptions and attitudes towards selective prevention actions. In WP7 the results of WP4-WP6 will be collated and synthesized into tailored designs for implementing selective prevention actions (inspired by the Dutch guideline) in the five fore-mentioned EU Member States with the aim to test their feasibility. The feasibility tests are the core element of WP8. This will result in a toolbox of measures to tailor the implementation of selective prevention actions in all EU Member States taking their respective social, cultural, political and health care system contexts into account
